论文部分内容阅读
目的：探讨恶性肿瘤患者治疗前后细胞免疫功能。方法：用双抗体夹心ＥＬＩＳＡ法检测４０例各类恶性肿瘤患者治疗前后血清ｓＩＬ－２Ｒ水平。结果：恶性肿瘤患者血清ｓＩＬ－２Ｒ水平为１５８５．９１±７５８．１５，显著高于正常人２３９．２２±８１．１３（Ｐ＜０．００１），经治疗６个月后（手术、放疗）各类肿瘤患者血清ｓＩＬ－２Ｒ较治疗前明显降低，值为６３６．２５±５７６．２５（Ｐ＜０．０５），但仍未降至正常水平。结论：血清ｓＩＬ－２Ｒ作为恶性肿瘤患者免疫功能的检测指标之一，对恶性肿瘤的诊断、治疗和预后的判断具有重要意义。
Objective: To investigate the cellular immune function before and after treatment in patients with malignant tumors. Methods: Serum sIL-2R levels were detected in 40 patients with various types of malignant tumor before and after treatment by double antibody sandwich ELISA. Results: The serum level of sIL-2R in patients with malignant tumors was 1585.91±758.15, which was significantly higher than that of normal subjects (239.22±81.13) (P<0.001). After 6 months of treatment (surgery and radiotherapy) The serum sIL-2R in patients with various tumors was significantly lower than before treatment, with a value of 636.25±576.25 (P<0.05), but it still did not fall to normal levels. Conclusion: Serum sIL-2R is one of the indicators of immunological function in patients with malignant tumors. It has important significance in the diagnosis, treatment and prognosis of malignant tumors.